In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jomed Stakes Out the US

Executive Summary

By all accounts, the one piece missing from the puzzle for Jomed NV, the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Thus, most industry observers saw the value in Jomed's merger with Endosonics as providing it with a US sales and marketing infrastructure.

You may also be interested in...



The Sorin Group: Europe's Last, Best Hope in Cardiovascular Devices

The contribution that Europeans, particularly European physicians and surgeons, have made to the cardiology and cardiovascular industries has been enormous. Why then have Europeans lagged far behind their US counterparts in one important area--company creation? If there is a candidate to play in the cardiovascular device industry's elite ranks, it's Sorin Group, a company with a diverse holding in a wide range of cardiology and cardiovascular device segments.

Millimed models Jomed in interventional neurology

Former Jomed CEO Tor Peters is back, trying to build another major device company, this time in interventional neurology and modeled after the strategy he used at Jomed.

Volcano Steps Up in Vulnerable Plaque By Buying Jomed's IVUS Business

For Volcano Therapeutics, the addition of Jomed's IVUS business is both an addition to and diversification beyond its current play in thermography as a diagnostic tool to detect vulnerable plaque.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV001490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel